1. Israel Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Evogene Ltd.

Evogene Ltd.

EVGN
Evogene Ltd.US flagNASDAQ Global Market
0.54
USD
-0.01
- -
4.63MMarket Cap

Total Valuation

Evogene Ltd. carries a market capitalization of 4.63M, placing it among publicly traded companies globally. Its enterprise value stands at 7.53M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap4.63M
Enterprise Value7.53M

Share Statistics

Evogene Ltd. currently has 10.41M shares outstanding.

Shares Outstanding10.41M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 3.59, and the price-to-book ratio stands at -3.15.

PE RatioN/A
PS Ratio3.59
PB Ratio-3.15
P/TBV Ratio-3.15
P/FCF Ratio-0.59
P/OCF Ratio-0.59

Enterprise Valuation

EV / Sales4.08
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

Evogene Ltd. maintains a current ratio of 2.79, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 25.42, indicating elevated leverage, while an interest coverage ratio of -3.66 demonstrates limited ability to service its debt obligations.

Current Ratio2.79
Quick Ratio2.75
Debt / Equity25.42
Debt / EBITDA-0.15
Interest Coverage-3.66

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)-45.04
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover2.33

Taxes

Income Tax6,000.00
Effective Tax RateN/A

Stock Price Statistics

Evogene Ltd.'s stock has declined approximately -55.175% over the past 52 weeks. The 50-day moving average sits at 0.53, while the 200-day moving average is 0.80.

Beta (5Y)N/A
52-Week Price Change-55.175%
50-Day Moving Average0.53
200-Day Moving Average0.80
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Evogene Ltd. generated 1.84M in revenue and converted that into -11.77M in net income, yielding earnings per share of -2.04. EBITDA reached -13.12M, while operating income came in at -14.16M.

Revenue1.84M
Gross Profit-863,000.00
Operating Income-14.16M
Pretax Income-17.50M
Net Income-11.77M
EBITDA-13.12M
EBIT-14.16M
Earnings Per Share (EPS)-2.04

Balance Sheet

Evogene Ltd. holds 13.05M in cash and equivalents against 2.03M in total debt, resulting in a net debt position of -8.51M. Total book value stands at -2.54M, with working capital of 9.60M providing operational flexibility.

Cash & Cash Equivalents13.05M
Total Debt2.03M
Net Debt-8.51M
Equity (Book Value)-2.54M
Book Value Per Share-0.24
Working Capital9.60M

Cash Flow

Evogene Ltd. produced -11.27M in operating cash flow over the past twelve months. After subtracting -16,000.00 in capital expenditures, free cash flow totaled -11.29M - equivalent to -1.31 per share.

Operating Cash Flow-11.27M
Capital Expenditures-16,000.00
Free Cash Flow-11.29M
FCF Per Share-1.31

Margins

Evogene Ltd. operates with a gross margin of -46.80, reflecting its pricing power and cost economics. The operating margin of -767.73 and net profit margin of -638.12 provide insight into operational efficiency.

Gross Margin-46.80
Operating Margin-767.73
Pretax Margin-949.02
Profit Margin-638.12
EBITDA Margin-711.55

Dividends & Yields

The company's payout ratio of -1.17 indicates the proportion of earnings distributed to shareholders.

Dividend Per Share0.02
Dividend YieldN/A
Payout Ratio-1.17
Shareholder Yield43.03
FCF Yield-170.01

Stock Splits

Evogene Ltd.'s most recent stock split took place on July 25, 2024 with a 10:1 split ratio.

Last Split Date7/25/2024
Split Ratio10:1

Scores

Evogene Ltd. posts an Altman Z-Score of -23.87, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-23.87